Related Experiment Video

Updated: Aug 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The effect of statins in heart failure: beyond its cholesterol-lowering effect

Kizhake C Kurian1, Prithviraj Rai, Sunder Sankaran

  • 1Division of Cardiology, University of Florida Health Science Center-Jacksonville, Jacksonville, Florida 32223, USA.

Journal of Cardiac Failure
|August 17, 2006
PubMed

Insights

Statins, or HMG-CoA reductase inhibitors, show promise in managing chronic heart failure by improving endothelial function and reducing inflammation. Further research is exploring their benefits in both ischemic and non-ischemic heart failure cases.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins (HMG-CoA reductase inhibitors) effectively lower plasma cholesterol.
  • They are prescribed for hypercholesterolemia, ischemic heart disease, and post-transplant care.
  • Potential roles in Alzheimer's dementia prevention, multiple sclerosis, and cancer risk reduction are also investigated.

Purpose of the Study:

  • To review current knowledge on statin utilization in heart failure patients.
  • To explore the established and emerging applications of statins in managing heart failure.

Main Methods:

  • This study is a comprehensive literature review.
  • It synthesizes existing research on statin therapy in various heart failure contexts.

Main Results:

  • Statin use in chronic heart failure is not yet fully established but shows promise.
  • Benefits are noted in patients with ischemic heart failure and emerging evidence supports their use in non-ischemic heart failure.
  • Statins offer pleiotropic effects, including plaque stabilization, improved endothelial function, anti-inflammatory actions, and enhanced autonomic function.

Conclusions:

  • Statins possess multifaceted properties beneficial for heart failure management.
  • Their role in improving cardiovascular outcomes in heart failure warrants continued investigation.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...